Blockchain Registration Transaction Record

Nutriband Files Patent to Extend AVERSA Abuse-Deterrent Tech Protection

Nutriband files patent to extend AVERSA abuse-deterrent transdermal technology protection for 20 years, enhancing safety for fentanyl patches and preventing drug misuse.

This development addresses the critical public health challenge of prescription drug abuse, particularly in the opioid crisis context. Abuse-deterrent technologies like AVERSA represent a vital balance between ensuring legitimate patient access to necessary pain medications while preventing misuse that contributes to addiction and overdose deaths. For healthcare providers, these innovations offer safer treatment options for patients requiring potent analgesics. For society, such technologies help reduce the diversion of prescription drugs into illicit markets and decrease accidental exposures that can lead to fatal outcomes. The extended patent protection ensures continued investment in safety innovations that benefit patients, healthcare systems, and communities grappling with substance abuse issues.